Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132301 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT00132301: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT00132301 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 298 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132301, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
Interventions
- DRUG Docetaxel
- DRUG Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2006-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132301
The ClinicalTrials.gov registry entry for NCT00132301 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00132301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132301 about?
NCT00132301 is a clinical study titled "Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma". VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surve...
What is the current status of trial NCT00132301?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2006-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT00132301?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT00132301?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.